LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

VOLUNTARY ANNOUNCEMENT
UPDATE ANNOUNCEMENT ON ACQUISITION OF ADDITIONAL EQUITY INTEREST IN NON-WHOLLY OWNED SUBSIDIARY LIVZON DIAGNOSTICS

Reference is made to the announcement of Livzon Pharmaceutical Group Inc.* 麗珠醫藥集團股份有限公司(the "**Company**", together with its subsidiaries, collectively referred to as the "**Group**") dated 17 November 2023 (the "**Announcement**") in relation to the Acquisitions. Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Announcement.

As at 21 November 2023, the Company has paid the respective consideration to Ms. Li and Mr. Shi respectively, and the Completion of the Target Equity Interest has been completed. As at the date of this announcement, the Company's equity interest in Livzon Diagnostics has increased from 39.43% to 47.43%.

This announcement is made voluntarily by the Company.

<div align="right">
By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary
</div>

Zhuhai, China

21 November 2023

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

* For identification purpose only